Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 EN COURS 
Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Voir le projet

 44

 EN COURS 
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Voir le projet

 43

 EN COURS 

Adaptive Bio-electronics for Chronic Cardiorespiratory Disease (CResPace)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

This consortium will pioneer disruptive technology for bio-electronic medicine to provide much needed therapies for cardiorespiratory and functional neurological disease. The technology implements small neural networks known as central pattern generators (CPG) to deliver fit-and-forget bio-electronic implants that respond to physiological feedback in real time, are safer, simpler, non-invasive, an ...
Voir le projet

 8

 EN COURS 
The hypothalamus is an essential interface among neuroendocrine, autonomic and somatomotor systems, allowing dynamic bodily adaptations to environmental cues via the orchestration of complex physiological processes. Hypothalamic nuclei exhibit unprecedented molecular, structural and functional diversity of neurons, reflecting the breadth of neuroendocrine output. To date, a significant portion of ...
Voir le projet

 1

 EN COURS 

Therapeutic approaches to enhance innate immunity against Tumors (TNT-TUMORS)

Date du début: 1 sept. 2016, Date de fin: 31 août 2021,

Recent advances using immune checkpoint inhibitors demonstrate the great potential of immunemodulation in cancer and metastasis treatment. However, the effective treatment of only a subset of patients shows that this is only the start to utilize the power of the immune system to fight cancer. An interesting approach is to harness innate immune cells, such as plasmacytoid dendritic cells (pDCs) and ...
Voir le projet

 1

 EN COURS 
Chronic angina pectoris is a debilitating chronic disease, a subgroup of these patients suffers from refractory angina which unfortunately can’t be controlled by medical therapy (angioplasty or surgery). Refractory angina is a substantial burden on the individual and healthcare system, in Europe there are 100,000 new cases per year, annual mortality of these patients is relatively low (
Voir le projet

 10

 EN COURS 
The physical laws of diffraction generally limit the spatial resolution of optical systems, being about 200 nm for light in the visible range. Within ChipScope we want to overcome this limit by developing the scientific and technological basis for a completely new approach to optical superresolution, based on semiconductor nano Light Emitting Diode (nanoLED) arrays with individual pixel operation. ...
Voir le projet

 7

 EN COURS 
The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society. The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is st ...
Voir le projet

 33

 EN COURS 
Pharmacogenomics is the study of genetic variability affecting an individual’s response to a drug. Its use allows personalized medicine and reduction in ‘trial and error’ prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx consortium will investigate a pre-emptive genotyping approach (that is: multiple pharmacogenomic variants are collected prospectively and ...
Voir le projet

 16

 EN COURS 

Hybrid optical and optoacoustic endoscope for esophageal tracking. (ESOTRAC)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

More than 450.000 people are diagnosed with esophageal cancer (EC) each-year worldwide and approximately 400.000 die from the disease. Esophageal cancer is the eighth most commonly diagnosed cancer, but it is the sixth leading cause of cancer-related death, with incidence rates steeply rising. Risk factors, including gastroesophageal reflux disease and Barrett’s esophagus, may diagnostically impli ...
Voir le projet

 9

 EN COURS 
Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of death or long-term disability in infants born at term in the western world, affecting about 1-4 per 1.000 life births and consequently about 5-20.000 infants per year in Europe.Hypothermic treatment became the only established therapy to improve outcome after perinatal hypoxic-ischemic insults. Despite hypothermia and neonatal inte ...
Voir le projet

 18

 EN COURS 
The EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry) emanates from the recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate certain tumors that do not respond to conventional treatment. To obtain T cells with reactivity to a wider array of tumors an ...
Voir le projet

 11

 EN COURS 
The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Voir le projet

 25

 EN COURS 

Technology Enabled Adolescent Mental Health (TEAM)

Date du début: 1 nov. 2016, Date de fin: 31 oct. 2020,

There is no health without mental health. 27% of our population are young, and mental health disorders are our leading cause of disability. 50% of mental disorders emerge by 14 yrs, 75% by 24 yrs and, untreated, triple odds of having a mental health disorder in later life. TEAM’s will build a network of expertise and train a new generation of researchers to deliver more effective, affordable and f ...
Voir le projet

 9

 EN COURS 

Multi-modal Optical Diagnostics for Ocular and Neurodegenerative Disease (MOON)

Date du début: 1 nov. 2016, Date de fin: 31 oct. 2020,

The rising life expectancy of EU citizens is creating a dramatic increase in age-related degenerative diseases and associated healthcare costs. The MOON Project (Multi-modal Optical Diagnostics for Ocular and Neurodegenerative Disease) meets this societal challenge by applying photonics to diagnose age-related diseases of the eye and central nervous system. Consistent with the ICT-29-2016: Photoni ...
Voir le projet

 6

 EN COURS 

Multimodal, Functional Bio-Photonic Imaging (FBI)

Date du début: 1 oct. 2016, Date de fin: 30 sept. 2020,

FBI fosters education of ESRs on an emerging, multimodal imaging platform and its translation into clinical and biological applications. In FBI, 15 ESRs are trained at world-leading European academic institutions and companies, thus forming strong interdisciplinary relations between industry, technical sciences and clinical end-users.Optical imaging has huge potential to address unmet clinical nee ...
Voir le projet

 10

 TERMINÉ 

Optical imaging of ocular pathology in Alzheimer’s disease (OPTIMALZ)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Novel diagnostic techniques and disease models have the powerful potential to provide new insights into pathological and pathophysiological processes. Ocular manifestations of Alzheimer’s disease (AD) emerge as novel and attractive alternative to investigate disease progression in parallel to the brain. Using the eye as a window to the brain, we propose to develop multi-functional optical coherenc ...
Voir le projet

 1

 TERMINÉ 
Recently we discovered an entirely new phenomenon in developmental biology – targeted recruitment of stem cells from the pervasive peripheral nerves. For example, we demonstrated that majority of melanocytes – our pigment cells, are born from peripheral glial cells. To further extend this far-reaching principle we will use tooth development as a model. Current opinion holds that sensory innervatio ...
Voir le projet

 1

 TERMINÉ 

The artificial pancreas in children aged 1 to 7 years with type 1 diabetes (KidsAP)

Date du début: 1 janv. 2017, Date de fin: 30 juin 2020,

TYPE 1 DIABETES is one of the most COMMON CHRONIC diseases in children with a RAPID increase in number of cases particularly in young children. Type 1 diabetes is associated with LIFE-LONG dependency on insulin administration. POOR glucose control leads to diabetes COMPLICATIONS, e.g. eye, heart, kidney disease, including BRAIN changes in young children. Episodes of VERY LOW glucose levels may be ...
Voir le projet

 14

 TERMINÉ 
The proposed European Concerted Programme on Radiation Protection Research (acronym: CONCERT) aims to contribute to the sustainable integration of European and national research programmes in radiation protection. It will do so by focusing resources and efforts in five key directions:• Bring together the elements of the European scientific communities in the fields of radiation effects and risks, ...
Voir le projet

 36

 TERMINÉ 
RELENT is multidisciplinary group of scientists and clinical investigators whose goal is to develop individualized treatment for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis, that cause considerable mortality and morbidity, both from uncontrolled disease and treatment associated co-morbidities, like infection and malignancy. This requires the need to stratify patients b ...
Voir le projet

 14

 TERMINÉ 
The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular disease (CVD), diabetes (DM), sarcopenia and cancer ...
Voir le projet

 13

 TERMINÉ 

Translating neuroimaging findings from research into clinical practice (PSYSCAN)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2020,

Abstract 9Neuroimaging (NI) has enormous potential to improve the clinical care of patients with psychiatric disorders, but has yet to deliver. The PSYSCAN project will address this issue directly by developing a NI-based tool that will help clinicians resolve key clinical issues in the management of patients with psychotic disorders. Clinicians will use the tool to assess patients with a standard ...
Voir le projet

 24

 TERMINÉ 
FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These nanodevices for folic acid (FA)-mediated targeting of activated macrophages showed improved clinical scores in a mouse model of RA when compared to methotrexate (MTX), a first-line drug therapy for the treatment of RA. In this way, FBN will be benchmarked agains ...
Voir le projet

 8

 TERMINÉ 

Digital Hybrid Breast PET/MRI for Enhanced Diagnosis of Breast Cancer (HYPMED)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Breast cancer represents a leading cause of cancer death in women and a major socio-economic issue. With currently available methods, early diagnosis frequently fails. Moreover, beyond mere detection, there is an ever-increasing need for improved non-invasive characterisation of cancer. Targeted therapies require an in-depth analysis of cancer to select and guide appropriate treatment. Both, PET a ...
Voir le projet

 10

 TERMINÉ 

Ophthalmic OCT on a Chip (OCTCHIP)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Silicon photonics is expected to leverage-off many of the advances made in CMOS electronics. International R&D efforts in this field have so far been mainly focused on the silicon-on-insulator (SOI) photonic integrated circuit (PIC) technology platform because it is predestined for datacom, high-performance computing and telecom applications. However, SOI based integrated optical waveguides cannot ...
Voir le projet

 7

 TERMINÉ 

Autologous Stem Cell Seeded Tissue Engineered Trachea (TETRA)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

CLINICAL PROBLEM AND UNMET NEEDThere are 11,827 patients with severe structural airway disease in Europe. Even with the current standard of care, when hospitalised this group of patients has a 22% risk of dying. Patients are currently subjected to repeated surgical interventions (stent insertion) which have a high failure rate. Other therapeutic strategies under development include synthetic trac ...
Voir le projet

 14

 TERMINÉ 

MRI and Ultrasound Robotic Assisted Biopsy (MURAB)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

The MURAB project has the ambition to revolutionise the way cancer screening and muscle diseases are researched for patients and has the potential to save lives by early detection and treatment.The project intends to create a new paradigm in which, the precision of great medical imaging modalities like MRI and Ultrasound are combined with the precision of robotics in order to target the right plac ...
Voir le projet

 8

 TERMINÉ 

Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE) (SCIENCE)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)With more than 17 million deaths worldwide each year, ischemic heart disease (IHD) caused by coronary artery disease is the most common cause of death and a major cause of hospital admissions in industrialised countries. IHD caused over four million deaths in Europe in the year 2012 constituting 47% of all deaths. Today IHD is th ...
Voir le projet

 9

 TERMINÉ 

European Network linking informatics and genomics of helper T cells (ENLIGHT-TEN)

Date du début: 1 oct. 2015, Date de fin: 30 sept. 2019,

ENLIGHT-TEN is a European Network Linking Informatics and Genomics of Helper T cells: our mission is to provide cross-disciplinary training in cellular immunology and big data analysis such that we train a new generation of researchers to fully exploit the power of emerging technological platforms. Our network of TEN beneficiaries combines T cell expertise with state-of-the-art technologies such a ...
Voir le projet

 11

 TERMINÉ 

Reseach Infrastructures Training Programme (RItrain)

Date du début: 1 sept. 2015, Date de fin: 31 août 2019,

There has never been a greater need for skilled managers and operators of research infrastructure (RI). Europe must develop the workforce that will turn ~50 nascent RIs with sites in different countries into powerhouses of support for major projects comparable to understanding the blueprint of life or discovering new subatomic particles. RItrain will develop a flagship training programme enabling ...
Voir le projet

 13

 TERMINÉ 
This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; www.erialcl.net) is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with exc ...
Voir le projet

 13

 TERMINÉ 

Coordinated Research Infrastructures Building Enduring Life-science services (CORBEL)

Date du début: 1 sept. 2015, Date de fin: 31 août 2019,

The social and economic challenges of ageing populations and chronic disease can only be met by translation of biomedical discoveries to new, innovative and cost effective treatments. The ESFRI Biological and Medical Research Infrastructures (BMS RI) underpin every step in this process; effectively joining scientific capabilities and shared services will transform the understanding of biological m ...
Voir le projet

 39

 TERMINÉ 

Integrating Technology into Mental Health Care Delivery in Europe (ICare)

Date du début: 1 sept. 2015, Date de fin: 31 août 2019,

The evidence base of Internet-based interventions in the prevention and treatment of mental health conditions has rapidly grown in the past decade. Yet many European countries (e.g., Germany, Austria, Switzerland, Great Britain, The Netherlands, Spain) have not implemented these promising approaches into health systems. Individuals with risk conditions or distinct mental health problems interested ...
Voir le projet

 13

 TERMINÉ 

A novel immunity-based test for early diagnosis of Lyme disease (ID-Lyme)

Date du début: 1 juil. 2016, Date de fin: 30 juin 2019,

The main objective of this ID-Lyme project is to push to the market a novel test, the Ixodes kit, for the early detection of Lyme Borreliosis (LB), also known as Lyme disease. LB can usually be treated using cost-effective antibiotics at an early stage of disease. Unfortunately, standard laboratory testing is often unable to give a clear diagnosis whether a patient is infected or not. This can res ...
Voir le projet

 5

 TERMINÉ 

Smart Resilience Indicators for Smart Critical Infrastructures (SmartResilience)

Date du début: 1 mai 2016, Date de fin: 30 avr. 2019,

"Modern critical infrastructures are becoming increasingly “smarter” (e.g. cities). Making the infrastructures “smarter” usually means making them smarter in normal operation and use: more adaptive, more intelligent… But will these smart critical infrastructures (SCIs) behave equally “smartly” and be “smartly resilient” also when exposed to extreme threats, such as extreme weather disasters or ter ...
Voir le projet

 21

 TERMINÉ 
"Epithelial ovarian cancer (EOC) is the most lethal gyncaecological malignancy causing 41900 deaths annually in Europe. The predominance of aggressive Type II tumours, which are characterised by a high frequency of p53 mutations, and primary or acquired resistance to platinum-based chemotherapy profoundly contribute to the high mortality rate. With current standard therapy the median overall survi ...
Voir le projet

 20

 TERMINÉ 
We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therape ...
Voir le projet

 30

 TERMINÉ 

Improving Design, Evaluation and Analysis of early drug development Studies (IDEAS)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

Drug development is a long and costly process which suffers from the major shortcoming that frequently failure is often only determined during the final stage. Recently, it has been recognised that more care needs to be taken during the early stages of development to avoid going into lengthy and costly confirmatory studies with ineffective or harmful treatments. To achieve this goal it is essentia ...
Voir le projet

 8

 TERMINÉ 

Vaccination In Atherosclerosis (VIA)

Date du début: 1 déc. 2013, Date de fin: 30 nov. 2018,

"Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%). In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU. Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underl ...
Voir le projet

 12